1. Home
  2. SOHU vs PROK Comparison

SOHU vs PROK Comparison

Compare SOHU & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sohu.com Limited

SOHU

Sohu.com Limited

HOLD

Current Price

$15.68

Market Cap

453.4M

Sector

Technology

ML Signal

HOLD

Logo ProKidney Corp.

PROK

ProKidney Corp.

HOLD

Current Price

$2.32

Market Cap

417.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOHU
PROK
Founded
1996
2015
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
453.4M
417.1M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
SOHU
PROK
Price
$15.68
$2.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$20.00
$6.25
AVG Volume (30 Days)
40.2K
1.4M
Earning Date
11-17-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
5.11
N/A
Revenue
$576,757,000.00
$744,000.00
Revenue This Year
N/A
$918.66
Revenue Next Year
$2.29
N/A
P/E Ratio
$3.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.79
$0.46
52 Week High
$16.45
$7.13

Technical Indicators

Market Signals
Indicator
SOHU
PROK
Relative Strength Index (RSI) 57.48 44.95
Support Level $14.94 $2.04
Resistance Level $15.90 $2.25
Average True Range (ATR) 0.68 0.19
MACD 0.09 0.04
Stochastic Oscillator 80.60 45.90

Price Performance

Historical Comparison
SOHU
PROK

About SOHU Sohu.com Limited

Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: